Literature DB >> 9276355

Radiation therapy for histologically confirmed primary central nervous system germinoma.

M G Haddock1, S E Schild, B W Scheithauer, P J Schomberg.   

Abstract

PURPOSE: To evaluate survival and patterns of recurrence in patients with primary central nervous system germinoma treated with radiation therapy. METHODS AND MATERIALS: Data regarding 48 patients with histologically confirmed, primary central nervous system germinoma were reviewed. All had been operated on at the Mayo Clinic between the years 1935 and 1993. Thirty-two patients (67%) were treated since 1973. The study group included 39 males and 9 females, with a median age at diagnosis of 17 years (range, 6-42 years). Twelve patients (25%) were treated with craniospinal axis irradiation, 11 (23%) received whole-brain irradiation without spinal axis irradiation, and 24 (50%) underwent partial-brain irradiation. Treatment volumes were unknown in one patient. The median dose to the primary tumor was 44.00 Gy (range, 7.44-59.40 Gy). The median follow-up was 5.5 years (range, 4 months to 37 years).
RESULTS: Actuarial 5-year and 10-year survival for the entire study group of patients was 80%. There was a trend toward improved survival in patients treated after 1973 (introduction of computed tomography) with 5-year and 10-year survival of 91% vs. 63% in prior years (p = 0.07). For the group of 31 patients treated since 1973 with known treatment volumes, the spinal axis failure rate at 5 years was 49% for patients treated with partial brain fields (11 patients) vs. 0% for those having undergone whole brain (10 patients) or craniospinal axis (10 patients) irradiation (p = 0.007). The rate of brain failure was also significantly higher in patients receiving less than whole-brain irradiation; at 5 years, 45% of the patients treated with partial-brain fields had intracranial recurrence of disease compared to 6 % of patients treated with craniospinal axis or whole-brain irradiation (p = 0.01). Among the 32 modern era patients, the rate of brain failure was higher in patients who received doses less than 40 Gy (median dose, 48.55 Gy; range, 30.60-59.40 Gy) to the primary tumor (5-year brain failure rate 52% vs. 11%, p = 0.002).
CONCLUSION: The long-term survival of patients with histologically proven CNS germinoma treated with radiation is excellent. Whole-brain or craniospinal axis irradiation appears to result in fewer spine and brain failures than does partial-brain irradiation. Furthermore, the administration of doses greater than 40 Gy to the primary tumor is associated with better local control.

Entities:  

Mesh:

Year:  1997        PMID: 9276355     DOI: 10.1016/s0360-3016(97)00135-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  27 in total

1.  Clinical outcomes of adult patients with primary intracranial germinomas treated with low-dose craniospinal radiotherapy and local boost.

Authors:  M Foote; B-A Millar; A Sahgal; C Ménard; D Payne; W Mason; N Laperriere
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

Review 2.  Recent advances in molecular biology and treatment strategies for intracranial germ cell tumors.

Authors:  Xiang Huang; Rong Zhang; Ying Mao; Liang-Fu Zhou; Chao Zhang
Journal:  World J Pediatr       Date:  2016-06-29       Impact factor: 2.764

3.  Central Nervous System Germ Cell Tumors.

Authors:  Regina Jakacki
Journal:  Curr Treat Options Neurol       Date:  2002-03       Impact factor: 3.598

4.  Salvage radiation therapy for intracranial germinoma recurring after primary chemotherapy.

Authors:  Y Shibamoto; K Sasai; M Kokubo; M Hiraoka
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

5.  Long-term outcome of patients with intracranial germinoma.

Authors:  Satoru Osuka; Koji Tsuboi; Shingo Takano; Eiichi Ishikawa; Akira Matsushita; Koichi Tokuuye; Yasuyuki Akine; Akira Matsumura
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.130

6.  Germinomas in the basal ganglia: magnetic resonance imaging classification and the prognosis.

Authors:  Ji Hoon Phi; Byung-Kyu Cho; Seung-Ki Kim; Jin Chul Paeng; In-One Kim; Il Han Kim; Dong Gyu Kim; Hee-Won Jung; Jeong Eun Kim; Kyu-Chang Wang
Journal:  J Neurooncol       Date:  2010-01-20       Impact factor: 4.130

7.  Long term outcomes in patients with intracranial germinomas: a single institution experience of irradiation with or without chemotherapy.

Authors:  Yasuhiro Kawabata; Jun A Takahashi; Yoshiki Arakawa; Mitsuaki Shirahata; Nobuo Hashimoto
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

Review 8.  Current advances in the diagnosis and management of intracranial germ cell tumors.

Authors:  Casilda Balmaceda; Jonathan Finlay
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

9.  Radiotherapy to primary CNS germinoma: how large an irradiated volume is justified for tumor control?

Authors:  Chen Kan Tseng; Ng Ming Tsang; Kuo Chen Wei; Tang Her Jaing; Ping Chin Pai; Tung Chieh Chang
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

10.  Treatment strategy for intracranial primary pure germinoma.

Authors:  Kyu-Won Shim; Eun Kyung Park; Yoon-Ho Lee; Chang-Ok Suh; Jaeho Cho; Joong-Uhn Choi; Dong-Seok Kim
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.